News | Nature Medicine: Study Identifies Four Distinct PCOS Subtypes, Paving the Way for Personalized Treatment
In a new study published in Nature Medicine, an international research team led by Karolinska Institutet in Sweden identified four distinct subtypes of polycystic ovary syndrome (PCOS) for the first time. The finding may enable more precise, personalized treatment for tens of millions of women with PCOS worldwide.
Polycystic ovary syndrome is a common endocrine and metabolic disorder that affects ovarian function and occurs in about 11% to 13% of women of reproductive age. PCOS has long been viewed as a heterogeneous syndrome with complex symptoms and diverse causes, but clear biological classification criteria have been lacking.
The team analyzed 6.5 years of clinical data from more than 11,900 patients with PCOS and validated its findings in five independent international cohorts from Asia, Europe, and the United States, confirming four clinically meaningful PCOS subtypes.
Features of the four PCOS subtypes
Based on clinical and physiological markers, the study divided PCOS into four subtypes:
HA-PCOS (high-androgen subtype)
Feature: Significantly elevated androgen levels.
Main risks: Highest second-trimester miscarriage rate and highest rate of dyslipidemia.
OB-PCOS (obesity subtype)
Features: High body mass index (BMI) and pronounced insulin resistance.
Main findings: Most severe metabolic problems and lowest live birth rate, but the highest rate of PCOS remission over time.
SHBG-PCOS (high sex hormone-binding globulin subtype)
Feature: Higher sex hormone-binding globulin (SHBG) levels.
Clinical profile: A relatively mild form of PCOS, with fewer fertility problems and the lowest risks of diabetes and hypertension.
LH-PCOS (high luteinizing hormone subtype)
Features: Elevated luteinizing hormone (LH) and anti-Müllerian hormone (AMH) levels.
Clinical profile: Highest risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and the lowest rate of spontaneous remission.
Subtype differences shape reproductive and metabolic outcomes
The study found significant differences among the four PCOS subtypes in pregnancy rates, live birth rates, and complication risks.
Patients with SHBG-PCOS had the best IVF outcomes, including higher pregnancy and live birth rates;
Patients with OB-PCOS and HA-PCOS were more likely to experience miscarriage and metabolic complications, including dyslipidemia and type 2 diabetes.
IVF strategies may need to be individualized
Elisabet Stener-Victorin, professor of reproductive physiology at Karolinska Institutet and one of the study leaders, said:
“Our study found that different PCOS subtypes respond very differently to IVF treatment.
For example, patients with high-androgen PCOS (HA-PCOS) had better pregnancy outcomes with frozen embryo transfer than with fresh embryo transfer, which may influence future fertility treatment strategies.”
A new era of personalized care: precise PCOS classification
The team also developed PcosX, an online classification tool based on nine standardized clinical measures. Doctors can use it to quickly assign patients to a subtype and inform subsequent treatment decisions.
Professor Stener-Victorin said:
“Identifying PCOS subtypes means we can finally apply precision medicine to women's reproductive health.
Future diagnosis, treatment, and follow-up will no longer use a one-size-fits-all approach, but will be tailored to each woman's individual risk profile.”
She added that the international collaborative study provides strong evidence that could change the clinical diagnosis, treatment, and long-term management of PCOS.
News | Nature Medicine: Study Identifies Four Distinct PCOS Subtypes, Paving the Way for Personalized Treatment
News | Nature Medicine: Study Identifies Four Distinct PCOS Subtypes, Paving the Way for Personalized Treatment
In a new study published in Nature Medicine, an international research team led by Karolinska Institutet in Sweden identified four distinct subtypes of polycystic ovary syndrome (PCOS) for the first time. The finding may enable more precise, personalized treatment for tens of millions of women with PCOS worldwide.
Polycystic ovary syndrome is a common endocrine and metabolic disorder that affects ovarian function and occurs in about 11% to 13% of women of reproductive age. PCOS has long been viewed as a heterogeneous syndrome with complex symptoms and diverse causes, but clear biological classification criteria have been lacking.
The team analyzed 6.5 years of clinical data from more than 11,900 patients with PCOS and validated its findings in five independent international cohorts from Asia, Europe, and the United States, confirming four clinically meaningful PCOS subtypes.
Features of the four PCOS subtypes
Based on clinical and physiological markers, the study divided PCOS into four subtypes:
HA-PCOS (high-androgen subtype)
Feature: Significantly elevated androgen levels.
Main risks: Highest second-trimester miscarriage rate and highest rate of dyslipidemia.
OB-PCOS (obesity subtype)
Features: High body mass index (BMI) and pronounced insulin resistance.
Main findings: Most severe metabolic problems and lowest live birth rate, but the highest rate of PCOS remission over time.
SHBG-PCOS (high sex hormone-binding globulin subtype)
Feature: Higher sex hormone-binding globulin (SHBG) levels.
Clinical profile: A relatively mild form of PCOS, with fewer fertility problems and the lowest risks of diabetes and hypertension.
LH-PCOS (high luteinizing hormone subtype)
Features: Elevated luteinizing hormone (LH) and anti-Müllerian hormone (AMH) levels.
Clinical profile: Highest risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and the lowest rate of spontaneous remission.
Subtype differences shape reproductive and metabolic outcomes
The study found significant differences among the four PCOS subtypes in pregnancy rates, live birth rates, and complication risks.
Patients with SHBG-PCOS had the best IVF outcomes, including higher pregnancy and live birth rates;
Patients with OB-PCOS and HA-PCOS were more likely to experience miscarriage and metabolic complications, including dyslipidemia and type 2 diabetes.
IVF strategies may need to be individualized
Elisabet Stener-Victorin, professor of reproductive physiology at Karolinska Institutet and one of the study leaders, said:
“Our study found that different PCOS subtypes respond very differently to IVF treatment.
For example, patients with high-androgen PCOS (HA-PCOS) had better pregnancy outcomes with frozen embryo transfer than with fresh embryo transfer, which may influence future fertility treatment strategies.”
A new era of personalized care: precise PCOS classification
The team also developed PcosX, an online classification tool based on nine standardized clinical measures. Doctors can use it to quickly assign patients to a subtype and inform subsequent treatment decisions.
Professor Stener-Victorin said:
“Identifying PCOS subtypes means we can finally apply precision medicine to women's reproductive health.
Future diagnosis, treatment, and follow-up will no longer use a one-size-fits-all approach, but will be tailored to each woman's individual risk profile.”
She added that the international collaborative study provides strong evidence that could change the clinical diagnosis, treatment, and long-term management of PCOS.
Story source:
Collected online